SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Apr 29, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: April 29, 2016 · CIK: 0001385818 · Accession: 0001144204-16-097518
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210144
Letter
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
April 29, 2016
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention:
Re: Aytu BioScience, Inc. Registration Statement on Form S-1 Filed March 11, 2016
6 File No. 333-210144
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Aytu BioScience, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) to May 2, 2016 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander M. Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com.
Please be advised that the amount of compensation to be paid to the underwriters and any other arrangements among the Registrant and the underwriters and other broker-dealers participating in the distribution, as described in the Registration Statement, have been reviewed to the extent required by the Financial Industry Regulatory Authority and such Authority has issued a statement expressing no objections to the compensation and other arrangements.
In connection with the foregoing, the Registrant hereby acknowledges the following:
• should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
• the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
• the Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
AYTU BIOSCIENCE, INC.
Show Raw Text
CORRESP
1
filename1.htm
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
April 29, 2016
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention:
Re: Aytu BioScience, Inc.
Registration Statement on Form S-1
Filed March 11, 2016
6 File No. 333-210144
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”), Aytu BioScience, Inc. (the “Registrant”) hereby requests that the
United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective
date of the above-referenced registration statement (the “Registration Statement”) to May 2, 2016 at 5:00 p.m. Eastern
Time, or as soon thereafter as practicable.
Once the Registration Statement is
effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander M.
Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the
effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com.
Please be advised that the amount of compensation
to be paid to the underwriters and any other arrangements among the Registrant and the underwriters and other broker-dealers participating
in the distribution, as described in the Registration Statement, have been reviewed to the extent required by the Financial Industry
Regulatory Authority and such Authority has issued a statement expressing no objections to the compensation and other arrangements.
In connection with the foregoing, the
Registrant hereby acknowledges the following:
• should
the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not
foreclose the Commission from taking any action with respect to the Registration Statement;
• the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective,
does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration
Statement; and
• the
Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
Very truly yours,
AYTU BIOSCIENCE, INC.
By:
/s/ Gregory
A. Gould
Gregory A. Gould
Chief Financial Officer